Published on
October 13, 2016
- 11:00 GMT
TG Therapeutics, Inc. Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to ...
FDA agrees that Overall Response Rate (ORR) data from revised GENUINE study can be used to request pre-BLA (Biologics License Application) meeting If results of the revised GENUINE study are positive, the Company plans to file a BLA for accelerated …
Distribution channels:
Conferences & Trade Fairs, Technology
